The Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors
| Autor: | Kelvin K. W. To, Ivan Hung, Carol H.Y. Fong, Chloe Y Y Cheung, Wing Sun Chow, David T W Lui, Alan Chun Hong Lee, Anthony Raymond Tam, Chi Ho Lee, Ching-Wan Lam, Yu Cho Woo, Tip Yin Ho, Kathryn C.B. Tan, Polly Pang, Chun Yiu Law, Karen S.L. Lam |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty interferon beta-1b Endocrinology Diabetes and Metabolism media_common.quotation_subject Thyrotropin Thyroid function tests Diseases of the endocrine glands. Clinical endocrinology Antibodies Cohort Studies Endocrinology Internal medicine Humans Medicine Clinical significance Survivors Original Research media_common Triiodothyronine thyroid gland medicine.diagnostic_test SARS-CoV-2 thyroid function tests business.industry Convalescence autoimmunity Interferon beta-1b Thyroid COVID-19 Middle Aged RC648-665 Thyroid Diseases Thyroid disorder COVID-19 Drug Treatment Thyroxine medicine.anatomical_structure Female Thyroid function business Follow-Up Studies Immunoglobulins Thyroid-Stimulating |
| Zdroj: | Frontiers in Endocrinology Frontiers in Endocrinology, Vol 12 (2021) |
| ISSN: | 1664-2392 |
| DOI: | 10.3389/fendo.2021.746602 |
| Popis: | BackgroundSome studies have indicated that interferon (IFN) may be valuable in COVID-19. We aimed to evaluate the impact of short-term IFN on incident thyroid dysfunction and autoimmunity among COVID-19 survivors.MethodsWe included consecutive adults without known thyroid disorder admitted to Queen Mary Hospital for COVID-19 from July 2020 to January 2021 who had thyroid function tests (TFTs) and anti-thyroid antibodies measured both on admission and at three months.Results226 patients were included (median age 55.0 years; 49.6% men): 135 were IFN-treated. There tended to be more abnormal TFTs upon reassessment in IFN-treated patients (8.1% vs 2.2%, p=0.080). 179 patients (65.4% IFN-treated) had a complete reassessment of anti-thyroid antibodies. There were significant increases in titres of both anti-thyroid peroxidase antibodies (anti-TPO: baseline 29.21 units [IQR: 14.97 – 67.14] vs reassessment 34.30 units [IQR: 18.82 – 94.65], pvs reassessment 9.14 units [IQR: 6.83 – 17.17], p=0.001) in the IFN-treated group but not IFN-naïve group. IFN treatment (standardised beta 0.245, p=0.001) was independently associated with changes in anti-TPO titre. Of the 143 patients negative for anti-TPO at baseline, 8 became anti-TPO positive upon reassessment (seven IFN-treated; one IFN-naïve). Incident anti-TPO positivity was more likely to be associated with abnormal TFTs upon reassessment (phi 0.188, p=0.025).ConclusionIFN for COVID-19 was associated with modest increases in anti-thyroid antibody titres, and a trend of more incident anti-TPO positivity and abnormal TFTs during convalescence. Our findings suggest that clinicians monitor the thyroid function and anti-thyroid antibodies among IFN-treated COVID-19 survivors, and call for further follow-up studies regarding the clinical significance of these changes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|